Bio-Path’s (BPTH) “Buy” Rating Reaffirmed at Roth Mkm

Roth Mkm reiterated their buy rating on shares of Bio-Path (NASDAQ:BPTH) in a research report released on Thursday morning, Benzinga reports. They currently have a $40.00 target price on the stock.

Separately, StockNews.com began coverage on Bio-Path in a report on Tuesday. They set a sell rating for the company.

Bio-Path Stock Performance

Shares of BPTH stock opened at $4.20 on Thursday. Bio-Path has a fifty-two week low of $2.70 and a fifty-two week high of $44.80. The stock has a 50 day moving average price of $5.50 and a two-hundred day moving average price of $8.53. The company has a market capitalization of $2.86 million, a P/E ratio of -0.10 and a beta of 0.35.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, meeting analysts’ consensus estimates of ($5.40). During the same period in the prior year, the company posted ($10.60) EPS. As a group, equities analysts predict that Bio-Path will post -18.71 earnings per share for the current year.

Hedge Funds Weigh In On Bio-Path

A number of hedge funds and other institutional investors have recently made changes to their positions in BPTH. Walleye Capital LLC bought a new position in shares of Bio-Path during the third quarter valued at approximately $77,000. Vanguard Group Inc. grew its stake in Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after purchasing an additional 117,914 shares during the period. Renaissance Technologies LLC purchased a new stake in Bio-Path in the second quarter worth $70,000. Citadel Advisors LLC purchased a new stake in Bio-Path in the third quarter worth $35,000. Finally, Virtu Financial LLC purchased a new stake in Bio-Path in the first quarter worth $38,000. Institutional investors own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.